 T. Reece
Concepts (578)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Spinal Cord Ischemia | 23 | 2022 | 63 | 10.280 |
Why?
| | Aorta, Thoracic | 36 | 2022 | 257 | 7.890 |
Why?
| | Reperfusion Injury | 22 | 2021 | 252 | 6.650 |
Why?
| | Spinal Cord | 20 | 2022 | 344 | 5.560 |
Why?
| | Blood Vessel Prosthesis Implantation | 16 | 2023 | 181 | 4.910 |
Why?
| | Aortic Aneurysm, Thoracic | 18 | 2023 | 122 | 4.830 |
Why?
| | Cardiac Surgical Procedures | 30 | 2022 | 414 | 4.270 |
Why?
| | Erythropoietin | 7 | 2018 | 72 | 3.700 |
Why?
| | Aortic Valve | 27 | 2021 | 396 | 3.670 |
Why?
| | Aortic Aneurysm | 10 | 2022 | 55 | 3.440 |
Why?
| | Paraplegia | 14 | 2023 | 52 | 3.410 |
Why?
| | Spinal Cord Injuries | 10 | 2022 | 173 | 3.260 |
Why?
| | Heart Valve Diseases | 10 | 2020 | 161 | 2.780 |
Why?
| | Diazoxide | 5 | 2021 | 22 | 2.750 |
Why?
| | Vascular Surgical Procedures | 10 | 2020 | 260 | 2.680 |
Why?
| | Thoracic Surgery | 12 | 2022 | 106 | 2.610 |
Why?
| | Cerebrovascular Circulation | 7 | 2022 | 219 | 2.420 |
Why?
| | Aortic Diseases | 8 | 2021 | 108 | 2.290 |
Why?
| | Receptors, Erythropoietin | 4 | 2018 | 22 | 2.270 |
Why?
| | Heart Valve Prosthesis Implantation | 11 | 2020 | 175 | 2.130 |
Why?
| | Neuroprotective Agents | 5 | 2018 | 102 | 1.960 |
Why?
| | Aorta | 11 | 2021 | 388 | 1.880 |
Why?
| | Dexmedetomidine | 5 | 2014 | 45 | 1.810 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 4 | 2014 | 24 | 1.740 |
Why?
| | Hypothermia, Induced | 5 | 2022 | 66 | 1.740 |
Why?
| | Surgeons | 5 | 2022 | 236 | 1.730 |
Why?
| | Cyclohexanecarboxylic Acids | 8 | 2008 | 22 | 1.670 |
Why?
| | Purines | 8 | 2008 | 158 | 1.560 |
Why?
| | Subclavian Artery | 5 | 2020 | 29 | 1.500 |
Why?
| | Postoperative Complications | 24 | 2022 | 2122 | 1.480 |
Why?
| | Cardiology | 5 | 2019 | 260 | 1.390 |
Why?
| | Circulatory Arrest, Deep Hypothermia Induced | 6 | 2022 | 21 | 1.370 |
Why?
| | Thoracic Surgical Procedures | 5 | 2022 | 57 | 1.370 |
Why?
| | Aortic Valve Stenosis | 13 | 2021 | 269 | 1.280 |
Why?
| | Neuroprotection | 3 | 2017 | 30 | 1.270 |
Why?
| | Heart Arrest, Induced | 4 | 2021 | 30 | 1.260 |
Why?
| | Aortic Valve Insufficiency | 5 | 2018 | 46 | 1.230 |
Why?
| | Microglia | 4 | 2013 | 198 | 1.220 |
Why?
| | Humans | 149 | 2023 | 114045 | 1.220 |
Why?
| | Toll-Like Receptor 4 | 11 | 2020 | 285 | 1.220 |
Why?
| | Endovascular Procedures | 7 | 2023 | 267 | 1.190 |
Why?
| | Mitral Valve | 6 | 2020 | 94 | 1.150 |
Why?
| | Mice, Inbred C57BL | 19 | 2021 | 4680 | 1.110 |
Why?
| | Dissection | 4 | 2020 | 51 | 1.030 |
Why?
| | Cardiopulmonary Bypass | 9 | 2022 | 174 | 0.990 |
Why?
| | Heart Transplantation | 9 | 2023 | 670 | 0.980 |
Why?
| | Ischemia | 5 | 2021 | 361 | 0.960 |
Why?
| | Disease Models, Animal | 17 | 2021 | 3498 | 0.960 |
Why?
| | Adenosine A2 Receptor Agonists | 6 | 2007 | 19 | 0.960 |
Why?
| | Up-Regulation | 6 | 2020 | 802 | 0.930 |
Why?
| | Heart Diseases | 5 | 2019 | 329 | 0.930 |
Why?
| | Intraoperative Neurophysiological Monitoring | 2 | 2021 | 15 | 0.920 |
Why?
| | Lung Transplantation | 7 | 2019 | 244 | 0.910 |
Why?
| | Receptors, Adrenergic, alpha-2 | 2 | 2013 | 14 | 0.870 |
Why?
| | Receptor, Adenosine A2A | 6 | 2008 | 20 | 0.850 |
Why?
| | Mice | 24 | 2021 | 14843 | 0.830 |
Why?
| | Male | 80 | 2023 | 55396 | 0.830 |
Why?
| | Animals | 41 | 2021 | 31565 | 0.810 |
Why?
| | Periodicals as Topic | 2 | 2015 | 180 | 0.780 |
Why?
| | Troponin I | 1 | 2022 | 68 | 0.780 |
Why?
| | STAT3 Transcription Factor | 3 | 2018 | 172 | 0.770 |
Why?
| | Treatment Outcome | 26 | 2023 | 9049 | 0.760 |
Why?
| | Anesthesiology | 3 | 2018 | 35 | 0.740 |
Why?
| | Perfusion | 5 | 2022 | 147 | 0.740 |
Why?
| | Signal Transduction | 14 | 2020 | 4501 | 0.720 |
Why?
| | Cardiovascular Abnormalities | 1 | 2020 | 11 | 0.690 |
Why?
| | Beauty | 1 | 2020 | 11 | 0.690 |
Why?
| | Aortic Rupture | 2 | 2018 | 25 | 0.690 |
Why?
| | Carotid Artery, Common | 1 | 2020 | 29 | 0.690 |
Why?
| | Thoracic Surgery, Video-Assisted | 1 | 2020 | 39 | 0.680 |
Why?
| | Calcinosis | 6 | 2018 | 239 | 0.680 |
Why?
| | Hospital Mortality | 14 | 2022 | 773 | 0.670 |
Why?
| | Nervous System Diseases | 2 | 2021 | 254 | 0.670 |
Why?
| | Societies, Medical | 9 | 2022 | 655 | 0.670 |
Why?
| | Politics | 1 | 2020 | 78 | 0.650 |
Why?
| | Reactive Oxygen Species | 2 | 2020 | 522 | 0.650 |
Why?
| | Acidosis | 1 | 2020 | 86 | 0.650 |
Why?
| | Blood Vessel Prosthesis | 6 | 2023 | 113 | 0.650 |
Why?
| | Spinal Cord Stimulation | 1 | 2019 | 7 | 0.650 |
Why?
| | Lower Extremity | 2 | 2014 | 334 | 0.640 |
Why?
| | Osteogenesis | 7 | 2019 | 181 | 0.640 |
Why?
| | Heart Arrest | 1 | 2022 | 293 | 0.640 |
Why?
| | Blood Transfusion | 3 | 2020 | 265 | 0.630 |
Why?
| | Retrospective Studies | 35 | 2023 | 12521 | 0.620 |
Why?
| | Nerve Growth Factor | 1 | 2018 | 27 | 0.610 |
Why?
| | Middle Aged | 49 | 2023 | 26605 | 0.590 |
Why?
| | CREB-Binding Protein | 2 | 2014 | 27 | 0.590 |
Why?
| | Population Surveillance | 1 | 2020 | 385 | 0.580 |
Why?
| | Anesthesia | 2 | 2016 | 117 | 0.580 |
Why?
| | Catheterization | 1 | 2018 | 158 | 0.570 |
Why?
| | Prosthesis Design | 1 | 2019 | 283 | 0.570 |
Why?
| | Neurons | 5 | 2020 | 1277 | 0.570 |
Why?
| | Catheterization, Peripheral | 2 | 2016 | 100 | 0.560 |
Why?
| | Nicorandil | 3 | 2021 | 10 | 0.560 |
Why?
| | Stents | 6 | 2023 | 466 | 0.560 |
Why?
| | Thoracotomy | 3 | 2014 | 73 | 0.530 |
Why?
| | Coronary Artery Bypass | 7 | 2016 | 196 | 0.520 |
Why?
| | Transcranial Direct Current Stimulation | 1 | 2015 | 4 | 0.510 |
Why?
| | Time Factors | 17 | 2023 | 6077 | 0.510 |
Why?
| | Evoked Potentials, Motor | 1 | 2015 | 34 | 0.500 |
Why?
| | Femoral Artery | 3 | 2015 | 165 | 0.500 |
Why?
| | Aged | 35 | 2023 | 18969 | 0.500 |
Why?
| | Imaging, Three-Dimensional | 1 | 2019 | 511 | 0.500 |
Why?
| | Clinical Protocols | 1 | 2016 | 232 | 0.490 |
Why?
| | Mitochondria | 1 | 2020 | 744 | 0.490 |
Why?
| | Chemokines | 2 | 2015 | 215 | 0.490 |
Why?
| | Tissue and Organ Procurement | 5 | 2023 | 226 | 0.480 |
Why?
| | Cardiovascular Surgical Procedures | 1 | 2014 | 29 | 0.470 |
Why?
| | Risk Factors | 15 | 2022 | 8614 | 0.470 |
Why?
| | Cell Survival | 7 | 2017 | 1014 | 0.470 |
Why?
| | Apoptosis | 4 | 2018 | 2349 | 0.460 |
Why?
| | Motor Activity | 3 | 2014 | 635 | 0.450 |
Why?
| | Cells, Cultured | 13 | 2021 | 3861 | 0.450 |
Why?
| | Heart Valve Prosthesis | 4 | 2018 | 122 | 0.450 |
Why?
| | Survival Rate | 12 | 2019 | 1638 | 0.440 |
Why?
| | Multimodal Imaging | 3 | 2019 | 89 | 0.440 |
Why?
| | Esophagus | 1 | 2015 | 224 | 0.440 |
Why?
| | Risk Assessment | 13 | 2020 | 2958 | 0.430 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2019 | 373 | 0.430 |
Why?
| | Tomography, X-Ray Computed | 2 | 2021 | 2272 | 0.420 |
Why?
| | Intermittent Claudication | 1 | 2014 | 108 | 0.420 |
Why?
| | Astrocytes | 1 | 2014 | 159 | 0.420 |
Why?
| | Cardiomyopathy, Dilated | 4 | 2020 | 350 | 0.410 |
Why?
| | Models, Cardiovascular | 2 | 2017 | 179 | 0.410 |
Why?
| | American Heart Association | 3 | 2019 | 264 | 0.410 |
Why?
| | Magnetic Resonance Spectroscopy | 3 | 2019 | 474 | 0.390 |
Why?
| | Acute Disease | 6 | 2021 | 907 | 0.390 |
Why?
| | Prognosis | 9 | 2022 | 3315 | 0.390 |
Why?
| | Pulmonary Valve | 1 | 2013 | 89 | 0.390 |
Why?
| | Acute Kidney Injury | 5 | 2022 | 637 | 0.390 |
Why?
| | Adult | 32 | 2023 | 30375 | 0.390 |
Why?
| | United States | 21 | 2023 | 12137 | 0.380 |
Why?
| | Cause of Death | 1 | 2013 | 362 | 0.380 |
Why?
| | Anesthetics | 1 | 2011 | 54 | 0.380 |
Why?
| | Vascular Diseases | 2 | 2016 | 233 | 0.380 |
Why?
| | Myelitis | 1 | 2012 | 88 | 0.370 |
Why?
| | Female | 50 | 2023 | 59324 | 0.370 |
Why?
| | Aorta, Abdominal | 1 | 2011 | 39 | 0.370 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 4 | 2020 | 907 | 0.360 |
Why?
| | Anti-Inflammatory Agents | 4 | 2013 | 445 | 0.360 |
Why?
| | Axillary Artery | 3 | 2018 | 12 | 0.360 |
Why?
| | Monitoring, Intraoperative | 3 | 2021 | 38 | 0.350 |
Why?
| | Replantation | 3 | 2019 | 33 | 0.350 |
Why?
| | Mitral Valve Insufficiency | 5 | 2015 | 69 | 0.340 |
Why?
| | Heart-Assist Devices | 5 | 2019 | 500 | 0.340 |
Why?
| | Aortic Arch Syndromes | 1 | 2009 | 2 | 0.340 |
Why?
| | Cardiovascular Diseases | 3 | 2019 | 1726 | 0.340 |
Why?
| | Simvastatin | 3 | 2019 | 58 | 0.340 |
Why?
| | Diverticulum | 1 | 2009 | 11 | 0.340 |
Why?
| | Pneumonectomy | 2 | 2008 | 121 | 0.330 |
Why?
| | Brachiocephalic Trunk | 3 | 2018 | 11 | 0.330 |
Why?
| | Lung | 7 | 2011 | 3521 | 0.320 |
Why?
| | Anastomosis, Surgical | 3 | 2019 | 135 | 0.320 |
Why?
| | Angiography | 3 | 2019 | 176 | 0.320 |
Why?
| | Proto-Oncogene Proteins c-akt | 4 | 2014 | 397 | 0.320 |
Why?
| | Heart | 5 | 2023 | 613 | 0.320 |
Why?
| | Adenocarcinoma | 5 | 2018 | 787 | 0.320 |
Why?
| | Regional Blood Flow | 4 | 2019 | 421 | 0.320 |
Why?
| | Phospholipases A2, Secretory | 3 | 2014 | 21 | 0.310 |
Why?
| | Muscle, Skeletal | 2 | 2015 | 1468 | 0.310 |
Why?
| | Extracorporeal Membrane Oxygenation | 3 | 2021 | 241 | 0.310 |
Why?
| | Echocardiography | 5 | 2019 | 569 | 0.300 |
Why?
| | Phosphorylation | 4 | 2018 | 1558 | 0.300 |
Why?
| | Esophageal Neoplasms | 4 | 2018 | 270 | 0.300 |
Why?
| | Peripheral Arterial Disease | 1 | 2014 | 381 | 0.300 |
Why?
| | Deglutition Disorders | 1 | 2009 | 117 | 0.300 |
Why?
| | Thrombocytopenia | 2 | 2020 | 177 | 0.300 |
Why?
| | Coronary Artery Disease | 3 | 2020 | 611 | 0.300 |
Why?
| | Heart Failure | 7 | 2019 | 1958 | 0.290 |
Why?
| | Hemodynamics | 4 | 2018 | 1015 | 0.290 |
Why?
| | Myofibroblasts | 3 | 2018 | 115 | 0.290 |
Why?
| | Adenosine A2 Receptor Antagonists | 2 | 2006 | 10 | 0.290 |
Why?
| | Collateral Circulation | 2 | 2019 | 18 | 0.290 |
Why?
| | Rabbits | 8 | 2008 | 733 | 0.290 |
Why?
| | Myocardial Ischemia | 4 | 2018 | 239 | 0.290 |
Why?
| | Follow-Up Studies | 10 | 2019 | 4392 | 0.270 |
Why?
| | Operative Time | 2 | 2019 | 106 | 0.270 |
Why?
| | Intraoperative Care | 2 | 2022 | 33 | 0.270 |
Why?
| | Stroke | 4 | 2023 | 1019 | 0.260 |
Why?
| | Hindlimb | 4 | 2012 | 130 | 0.260 |
Why?
| | Suture Techniques | 5 | 2020 | 115 | 0.260 |
Why?
| | Cell Culture Techniques | 3 | 2019 | 341 | 0.260 |
Why?
| | Organ Preservation Solutions | 2 | 2023 | 37 | 0.260 |
Why?
| | Catheterization, Central Venous | 1 | 2006 | 83 | 0.250 |
Why?
| | Syndrome | 3 | 2021 | 330 | 0.250 |
Why?
| | Myocardium | 4 | 2020 | 911 | 0.240 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2013 | 1128 | 0.240 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 2015 | 787 | 0.240 |
Why?
| | Recombinant Proteins | 4 | 2018 | 1228 | 0.240 |
Why?
| | Coronary Vessel Anomalies | 2 | 2016 | 31 | 0.240 |
Why?
| | Tissue Adhesives | 2 | 2018 | 16 | 0.230 |
Why?
| | Toll-Like Receptor 2 | 3 | 2020 | 110 | 0.220 |
Why?
| | Coronary Vessels | 2 | 2018 | 234 | 0.220 |
Why?
| | Length of Stay | 6 | 2020 | 957 | 0.220 |
Why?
| | Constriction | 3 | 2013 | 45 | 0.220 |
Why?
| | Endoleak | 2 | 2023 | 13 | 0.220 |
Why?
| | NF-kappa B | 6 | 2020 | 636 | 0.220 |
Why?
| | Primary Graft Dysfunction | 1 | 2023 | 29 | 0.220 |
Why?
| | Brain-Derived Neurotrophic Factor | 2 | 2014 | 106 | 0.210 |
Why?
| | Aortography | 3 | 2019 | 50 | 0.210 |
Why?
| | Consensus | 3 | 2020 | 532 | 0.210 |
Why?
| | Time-to-Treatment | 2 | 2022 | 146 | 0.210 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2014 | 211 | 0.210 |
Why?
| | Analysis of Variance | 3 | 2019 | 1218 | 0.210 |
Why?
| | Drug Evaluation, Preclinical | 3 | 2018 | 159 | 0.210 |
Why?
| | Educational Personnel | 1 | 2022 | 13 | 0.200 |
Why?
| | Blotting, Western | 4 | 2018 | 1143 | 0.200 |
Why?
| | Fibrosis | 3 | 2020 | 452 | 0.200 |
Why?
| | Cohort Studies | 6 | 2020 | 4883 | 0.200 |
Why?
| | Reoperation | 4 | 2014 | 513 | 0.190 |
Why?
| | Pleural Effusion | 1 | 2022 | 46 | 0.190 |
Why?
| | Echocardiography, Transesophageal | 2 | 2013 | 90 | 0.190 |
Why?
| | Renal Insufficiency | 1 | 2023 | 137 | 0.190 |
Why?
| | Inflammation | 5 | 2014 | 2464 | 0.190 |
Why?
| | Carbon Dioxide | 3 | 2016 | 218 | 0.190 |
Why?
| | Kaplan-Meier Estimate | 3 | 2019 | 813 | 0.190 |
Why?
| | Survival Analysis | 3 | 2013 | 1206 | 0.190 |
Why?
| | Wounds, Nonpenetrating | 1 | 2004 | 249 | 0.190 |
Why?
| | Cytokines | 3 | 2014 | 1824 | 0.190 |
Why?
| | Shock, Cardiogenic | 2 | 2020 | 55 | 0.190 |
Why?
| | Propensity Score | 2 | 2019 | 225 | 0.190 |
Why?
| | Mentors | 1 | 2023 | 155 | 0.190 |
Why?
| | Potassium Channels | 1 | 2021 | 121 | 0.180 |
Why?
| | KATP Channels | 1 | 2021 | 16 | 0.180 |
Why?
| | General Surgery | 1 | 2022 | 125 | 0.180 |
Why?
| | Intraoperative Complications | 2 | 2017 | 120 | 0.180 |
Why?
| | Lipopeptides | 1 | 2020 | 14 | 0.180 |
Why?
| | Interprofessional Relations | 1 | 2023 | 246 | 0.180 |
Why?
| | Quality Assurance, Health Care | 2 | 2013 | 308 | 0.180 |
Why?
| | Vascular Grafting | 1 | 2020 | 12 | 0.180 |
Why?
| | Practice Guidelines as Topic | 3 | 2013 | 1381 | 0.180 |
Why?
| | Minimally Invasive Surgical Procedures | 3 | 2019 | 154 | 0.180 |
Why?
| | Incidence | 6 | 2020 | 2314 | 0.180 |
Why?
| | Peroxidase | 3 | 2005 | 161 | 0.180 |
Why?
| | Arrhythmias, Cardiac | 2 | 2020 | 282 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2013 | 475 | 0.180 |
Why?
| | Cell Proliferation | 4 | 2020 | 2173 | 0.170 |
Why?
| | Cell Adhesion | 2 | 2018 | 426 | 0.170 |
Why?
| | Cardiomyopathies | 2 | 2019 | 298 | 0.170 |
Why?
| | Surgical Instruments | 1 | 2020 | 48 | 0.170 |
Why?
| | Aortitis | 1 | 2019 | 8 | 0.160 |
Why?
| | Adenosine Triphosphate | 1 | 2021 | 428 | 0.160 |
Why?
| | Loeys-Dietz Syndrome | 1 | 2019 | 6 | 0.160 |
Why?
| | Ultrasonography, Interventional | 1 | 2020 | 120 | 0.160 |
Why?
| | Patient Selection | 4 | 2019 | 629 | 0.160 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 146 | 0.160 |
Why?
| | Tricuspid Valve | 1 | 2019 | 27 | 0.160 |
Why?
| | Internship and Residency | 3 | 2020 | 920 | 0.160 |
Why?
| | Swine | 3 | 2006 | 687 | 0.160 |
Why?
| | Creatinine | 1 | 2020 | 424 | 0.150 |
Why?
| | RNA, Neoplasm | 1 | 2018 | 80 | 0.150 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 268 | 0.150 |
Why?
| | Documentation | 1 | 2020 | 166 | 0.150 |
Why?
| | Filamins | 1 | 2018 | 19 | 0.150 |
Why?
| | Terminology as Topic | 1 | 2019 | 186 | 0.150 |
Why?
| | Drug Synergism | 1 | 2018 | 315 | 0.150 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 2 | 2021 | 145 | 0.150 |
Why?
| | Electrocardiography | 2 | 2017 | 561 | 0.140 |
Why?
| | Phenotype | 8 | 2020 | 2784 | 0.140 |
Why?
| | ADAMTS5 Protein | 1 | 2017 | 5 | 0.140 |
Why?
| | Transcriptome | 2 | 2020 | 723 | 0.140 |
Why?
| | Hemostatics | 1 | 2018 | 44 | 0.140 |
Why?
| | Blood Loss, Surgical | 1 | 2018 | 82 | 0.140 |
Why?
| | Surface-Active Agents | 1 | 2018 | 79 | 0.140 |
Why?
| | Blood Pressure | 3 | 2018 | 1531 | 0.140 |
Why?
| | Cell Transdifferentiation | 1 | 2017 | 31 | 0.140 |
Why?
| | Graft Survival | 2 | 2023 | 443 | 0.140 |
Why?
| | Core Binding Factor Alpha 1 Subunit | 4 | 2019 | 40 | 0.140 |
Why?
| | Oxygen Consumption | 3 | 2016 | 587 | 0.140 |
Why?
| | Immunity, Cellular | 1 | 2018 | 247 | 0.140 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2020 | 1145 | 0.140 |
Why?
| | Lipopolysaccharides | 3 | 2019 | 813 | 0.140 |
Why?
| | Vasodilator Agents | 1 | 2018 | 302 | 0.140 |
Why?
| | Biomarkers | 4 | 2022 | 3397 | 0.140 |
Why?
| | Databases, Factual | 3 | 2020 | 1125 | 0.140 |
Why?
| | Registries | 2 | 2016 | 1764 | 0.130 |
Why?
| | Nitric Oxide | 1 | 2021 | 817 | 0.130 |
Why?
| | Sinus of Valsalva | 1 | 2016 | 11 | 0.130 |
Why?
| | Osteoblasts | 1 | 2017 | 106 | 0.130 |
Why?
| | Administration, Oral | 1 | 2018 | 725 | 0.130 |
Why?
| | Histone Deacetylases | 1 | 2018 | 194 | 0.130 |
Why?
| | Alkaline Phosphatase | 4 | 2019 | 142 | 0.130 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2020 | 445 | 0.130 |
Why?
| | Organ Sparing Treatments | 1 | 2016 | 31 | 0.130 |
Why?
| | Heart Atria | 1 | 2016 | 107 | 0.130 |
Why?
| | Glucose | 3 | 2023 | 899 | 0.130 |
Why?
| | Graft Rejection | 2 | 2023 | 511 | 0.130 |
Why?
| | Patient Safety | 1 | 2019 | 273 | 0.130 |
Why?
| | Mice, Inbred C3H | 2 | 2013 | 242 | 0.130 |
Why?
| | Heart Ventricles | 3 | 2017 | 723 | 0.130 |
Why?
| | Tissue Donors | 2 | 2023 | 314 | 0.130 |
Why?
| | Ventricular Function, Right | 1 | 2017 | 256 | 0.120 |
Why?
| | Decompression, Surgical | 2 | 2008 | 92 | 0.120 |
Why?
| | Case-Control Studies | 6 | 2018 | 3003 | 0.120 |
Why?
| | Interleukins | 1 | 2017 | 236 | 0.120 |
Why?
| | Glial Cell Line-Derived Neurotrophic Factor | 1 | 2014 | 16 | 0.120 |
Why?
| | Neutrophil Activation | 2 | 2005 | 78 | 0.120 |
Why?
| | Myocardial Infarction | 2 | 2016 | 932 | 0.120 |
Why?
| | Ventricular Dysfunction, Right | 1 | 2017 | 221 | 0.120 |
Why?
| | Myocardial Reperfusion Injury | 1 | 2015 | 95 | 0.120 |
Why?
| | Asphyxia | 1 | 2014 | 21 | 0.120 |
Why?
| | Kidney Failure, Chronic | 1 | 2019 | 489 | 0.120 |
Why?
| | Microtubule-Associated Proteins | 2 | 2006 | 171 | 0.120 |
Why?
| | Matrix Metalloproteinases | 1 | 2015 | 89 | 0.110 |
Why?
| | Comorbidity | 3 | 2020 | 1447 | 0.110 |
Why?
| | Extracellular Matrix Proteins | 1 | 2015 | 126 | 0.110 |
Why?
| | Brain Ischemia | 1 | 2017 | 297 | 0.110 |
Why?
| | Aortic Coarctation | 2 | 2006 | 70 | 0.110 |
Why?
| | Vascular Patency | 1 | 2014 | 97 | 0.110 |
Why?
| | Limb Salvage | 1 | 2014 | 51 | 0.110 |
Why?
| | Radiography | 2 | 2006 | 803 | 0.110 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2011 | 147 | 0.110 |
Why?
| | Calcium-Binding Proteins | 1 | 2015 | 205 | 0.110 |
Why?
| | Microfilament Proteins | 1 | 2014 | 125 | 0.110 |
Why?
| | Arterial Occlusive Diseases | 1 | 2014 | 75 | 0.110 |
Why?
| | Ligation | 1 | 2013 | 75 | 0.110 |
Why?
| | Thrombosis | 2 | 2019 | 295 | 0.110 |
Why?
| | Transcatheter Aortic Valve Replacement | 1 | 2015 | 152 | 0.110 |
Why?
| | Oxygen | 4 | 2006 | 851 | 0.110 |
Why?
| | Pericardium | 2 | 2011 | 50 | 0.110 |
Why?
| | Nerve Degeneration | 1 | 2013 | 41 | 0.110 |
Why?
| | Minocycline | 1 | 2013 | 26 | 0.110 |
Why?
| | Polyethylene Glycols | 1 | 2018 | 561 | 0.110 |
Why?
| | Transplantation, Autologous | 1 | 2013 | 175 | 0.100 |
Why?
| | Vascular Stiffness | 1 | 2017 | 410 | 0.100 |
Why?
| | Mice, Knockout | 3 | 2017 | 2562 | 0.100 |
Why?
| | Sleep Deprivation | 2 | 2005 | 167 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2021 | 1175 | 0.100 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2015 | 244 | 0.100 |
Why?
| | Consumer Health Information | 1 | 2013 | 47 | 0.100 |
Why?
| | Pulmonary Emphysema | 1 | 2015 | 267 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2013 | 164 | 0.100 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 366 | 0.100 |
Why?
| | Gene Expression Profiling | 1 | 2018 | 1518 | 0.100 |
Why?
| | Delivery of Health Care | 2 | 2023 | 828 | 0.100 |
Why?
| | Pulmonary Edema | 3 | 2011 | 109 | 0.100 |
Why?
| | Specialties, Surgical | 1 | 2013 | 67 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2014 | 2159 | 0.100 |
Why?
| | Foam Cells | 1 | 2011 | 13 | 0.100 |
Why?
| | Aged, 80 and over | 5 | 2018 | 6306 | 0.090 |
Why?
| | Warm Ischemia | 1 | 2011 | 11 | 0.090 |
Why?
| | Lung Diseases | 2 | 2008 | 690 | 0.090 |
Why?
| | Radiation Injuries | 1 | 2012 | 128 | 0.090 |
Why?
| | Enzyme Inhibitors | 2 | 2013 | 743 | 0.090 |
Why?
| | Physician's Role | 1 | 2013 | 192 | 0.090 |
Why?
| | Macrophages, Peritoneal | 1 | 2011 | 93 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 600 | 0.090 |
Why?
| | Interleukin-1beta | 1 | 2013 | 368 | 0.090 |
Why?
| | Lipoproteins, LDL | 1 | 2011 | 127 | 0.090 |
Why?
| | Coronary Artery Bypass, Off-Pump | 1 | 2010 | 15 | 0.090 |
Why?
| | Echocardiography, Three-Dimensional | 1 | 2011 | 49 | 0.090 |
Why?
| | Age Factors | 3 | 2020 | 2885 | 0.090 |
Why?
| | Neoplastic Stem Cells | 1 | 2014 | 327 | 0.090 |
Why?
| | Organ Preservation | 2 | 2023 | 64 | 0.090 |
Why?
| | United States Food and Drug Administration | 1 | 2011 | 172 | 0.090 |
Why?
| | Cell Movement | 1 | 2014 | 863 | 0.090 |
Why?
| | Ultrasonography | 1 | 2013 | 635 | 0.090 |
Why?
| | Interleukin 1 Receptor Antagonist Protein | 1 | 2011 | 253 | 0.080 |
Why?
| | Mitral Valve Prolapse | 1 | 2009 | 8 | 0.080 |
Why?
| | Prospective Studies | 4 | 2023 | 6195 | 0.080 |
Why?
| | Bone Morphogenetic Protein 2 | 3 | 2017 | 74 | 0.080 |
Why?
| | Heart Aneurysm | 2 | 2011 | 8 | 0.080 |
Why?
| | Platelet Aggregation Inhibitors | 1 | 2012 | 395 | 0.080 |
Why?
| | Critical Illness | 1 | 2014 | 640 | 0.080 |
Why?
| | Equipment Failure | 1 | 2009 | 107 | 0.080 |
Why?
| | Liver Transplantation | 1 | 2015 | 695 | 0.080 |
Why?
| | Surveys and Questionnaires | 2 | 2020 | 4595 | 0.080 |
Why?
| | Brain | 1 | 2020 | 2355 | 0.080 |
Why?
| | Percutaneous Coronary Intervention | 1 | 2014 | 445 | 0.080 |
Why?
| | Hypoxia | 1 | 2014 | 956 | 0.080 |
Why?
| | Collagen | 2 | 2020 | 414 | 0.080 |
Why?
| | Cell Line, Tumor | 4 | 2018 | 2700 | 0.080 |
Why?
| | Work Schedule Tolerance | 2 | 2005 | 35 | 0.070 |
Why?
| | Perfusion Imaging | 2 | 2018 | 51 | 0.070 |
Why?
| | Blood Preservation | 1 | 2011 | 231 | 0.070 |
Why?
| | Organ Size | 2 | 2006 | 434 | 0.070 |
Why?
| | Atherosclerosis | 1 | 2011 | 342 | 0.070 |
Why?
| | Mutation | 1 | 2018 | 3338 | 0.070 |
Why?
| | Statistics, Nonparametric | 1 | 2008 | 384 | 0.070 |
Why?
| | Heart Septal Defects | 1 | 2006 | 10 | 0.070 |
Why?
| | Reperfusion | 1 | 2006 | 35 | 0.070 |
Why?
| | Heart Defects, Congenital | 1 | 2013 | 683 | 0.070 |
Why?
| | Decision Making | 1 | 2013 | 760 | 0.070 |
Why?
| | Magnetic Resonance Imaging, Cine | 2 | 2017 | 172 | 0.070 |
Why?
| | Computed Tomography Angiography | 2 | 2018 | 100 | 0.070 |
Why?
| | Europe | 2 | 2018 | 332 | 0.070 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 1 | 2014 | 959 | 0.070 |
Why?
| | Triazines | 1 | 2006 | 36 | 0.070 |
Why?
| | Blood Flow Velocity | 2 | 2018 | 388 | 0.070 |
Why?
| | Hemiplegia | 1 | 2006 | 18 | 0.070 |
Why?
| | Magnetic Resonance Angiography | 2 | 2018 | 221 | 0.060 |
Why?
| | Probability | 1 | 2006 | 286 | 0.060 |
Why?
| | Intensive Care Units | 2 | 2020 | 614 | 0.060 |
Why?
| | Cardiac Catheterization | 1 | 2009 | 545 | 0.060 |
Why?
| | Needs Assessment | 1 | 2007 | 315 | 0.060 |
Why?
| | Methylprednisolone | 1 | 2006 | 80 | 0.060 |
Why?
| | Nitric Oxide Synthase | 1 | 2006 | 209 | 0.060 |
Why?
| | Triazoles | 1 | 2006 | 125 | 0.060 |
Why?
| | Blood Gas Analysis | 1 | 2005 | 70 | 0.060 |
Why?
| | Severity of Illness Index | 4 | 2005 | 2537 | 0.060 |
Why?
| | Receptors, Adenosine A2 | 1 | 2004 | 6 | 0.060 |
Why?
| | Actins | 2 | 2017 | 376 | 0.060 |
Why?
| | Cardiac Output | 1 | 2005 | 143 | 0.060 |
Why?
| | Predictive Value of Tests | 2 | 2020 | 1791 | 0.060 |
Why?
| | Random Allocation | 1 | 2005 | 328 | 0.060 |
Why?
| | Recovery of Function | 1 | 2008 | 573 | 0.060 |
Why?
| | Models, Animal | 1 | 2006 | 340 | 0.060 |
Why?
| | Sleep Disorders, Circadian Rhythm | 1 | 2004 | 37 | 0.060 |
Why?
| | RNA Interference | 2 | 2017 | 431 | 0.060 |
Why?
| | Paraparesis | 1 | 2023 | 6 | 0.060 |
Why?
| | Transfection | 2 | 2017 | 863 | 0.050 |
Why?
| | Thoracic Outlet Syndrome | 1 | 2003 | 12 | 0.050 |
Why?
| | Respiratory Function Tests | 1 | 2005 | 522 | 0.050 |
Why?
| | Brain Death | 1 | 2023 | 30 | 0.050 |
Why?
| | Morbidity | 2 | 2020 | 277 | 0.050 |
Why?
| | Vasodilation | 1 | 2006 | 418 | 0.050 |
Why?
| | Travel | 1 | 2023 | 121 | 0.050 |
Why?
| | Virginia | 3 | 2010 | 50 | 0.050 |
Why?
| | Aortic Aneurysm, Abdominal | 1 | 2003 | 113 | 0.050 |
Why?
| | Antithrombins | 1 | 2022 | 49 | 0.050 |
Why?
| | Cyanoacrylates | 1 | 2001 | 4 | 0.050 |
Why?
| | Ulcer | 1 | 2021 | 28 | 0.050 |
Why?
| | Ventricular Remodeling | 1 | 2003 | 224 | 0.050 |
Why?
| | Glutaral | 1 | 2001 | 14 | 0.050 |
Why?
| | Fibrin Tissue Adhesive | 1 | 2001 | 13 | 0.050 |
Why?
| | Hematoma | 1 | 2021 | 50 | 0.050 |
Why?
| | Death | 1 | 2022 | 106 | 0.050 |
Why?
| | Contraindications | 1 | 2001 | 84 | 0.050 |
Why?
| | Antioxidants | 1 | 2005 | 529 | 0.050 |
Why?
| | Drainage | 1 | 2022 | 145 | 0.050 |
Why?
| | Young Adult | 4 | 2018 | 10444 | 0.050 |
Why?
| | Antineoplastic Agents | 1 | 2011 | 1875 | 0.050 |
Why?
| | Seizures | 1 | 2023 | 337 | 0.050 |
Why?
| | A549 Cells | 1 | 2020 | 51 | 0.040 |
Why?
| | Immunohistochemistry | 2 | 2018 | 1624 | 0.040 |
Why?
| | Tumor Cells, Cultured | 2 | 2013 | 845 | 0.040 |
Why?
| | Aftercare | 1 | 2022 | 186 | 0.040 |
Why?
| | Warfarin | 1 | 2021 | 136 | 0.040 |
Why?
| | Endothelium, Vascular | 1 | 2006 | 830 | 0.040 |
Why?
| | Forecasting | 1 | 2001 | 331 | 0.040 |
Why?
| | Sensitivity and Specificity | 2 | 2020 | 1690 | 0.040 |
Why?
| | Adaptor Proteins, Vesicular Transport | 1 | 2019 | 44 | 0.040 |
Why?
| | Ventricular Function, Left | 2 | 2018 | 477 | 0.040 |
Why?
| | Principal Component Analysis | 1 | 2020 | 177 | 0.040 |
Why?
| | beta Catenin | 1 | 2021 | 218 | 0.040 |
Why?
| | Myeloid Differentiation Factor 88 | 1 | 2019 | 90 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 288 | 0.040 |
Why?
| | Ventricular Dysfunction, Left | 2 | 2018 | 371 | 0.040 |
Why?
| | Thrombectomy | 1 | 2019 | 52 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 1836 | 0.040 |
Why?
| | Transforming Growth Factor beta1 | 1 | 2020 | 153 | 0.040 |
Why?
| | Age Distribution | 1 | 2019 | 341 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2020 | 217 | 0.040 |
Why?
| | Sex Distribution | 1 | 2019 | 336 | 0.040 |
Why?
| | Reimbursement Mechanisms | 1 | 2019 | 76 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2022 | 459 | 0.040 |
Why?
| | Rats, Sprague-Dawley | 2 | 2018 | 2182 | 0.040 |
Why?
| | Substance Abuse, Intravenous | 1 | 2019 | 100 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2020 | 452 | 0.040 |
Why?
| | Clinical Competence | 2 | 2020 | 882 | 0.040 |
Why?
| | Gelatin Sponge, Absorbable | 1 | 2018 | 5 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2022 | 1656 | 0.040 |
Why?
| | Connectin | 1 | 2018 | 30 | 0.040 |
Why?
| | Hemostasis, Surgical | 1 | 2018 | 19 | 0.040 |
Why?
| | Washington | 1 | 2018 | 134 | 0.040 |
Why?
| | Risk | 1 | 2020 | 810 | 0.040 |
Why?
| | Flow Cytometry | 2 | 2011 | 1075 | 0.040 |
Why?
| | Hydroxamic Acids | 1 | 2018 | 80 | 0.040 |
Why?
| | Primary Cell Culture | 1 | 2018 | 148 | 0.040 |
Why?
| | Respiratory Insufficiency | 1 | 2021 | 286 | 0.040 |
Why?
| | Myosins | 1 | 2018 | 125 | 0.040 |
Why?
| | Advisory Committees | 1 | 2019 | 207 | 0.040 |
Why?
| | Patient-Specific Modeling | 1 | 2017 | 37 | 0.040 |
Why?
| | Matrilin Proteins | 1 | 2017 | 7 | 0.040 |
Why?
| | Sp7 Transcription Factor | 1 | 2017 | 7 | 0.040 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 926 | 0.040 |
Why?
| | Antagomirs | 1 | 2017 | 13 | 0.040 |
Why?
| | Cross-Linking Reagents | 1 | 2018 | 179 | 0.030 |
Why?
| | Potassium | 1 | 1997 | 127 | 0.030 |
Why?
| | NFATC Transcription Factors | 1 | 2017 | 78 | 0.030 |
Why?
| | Microscopy, Fluorescence | 1 | 2018 | 393 | 0.030 |
Why?
| | DNA Mutational Analysis | 1 | 2018 | 373 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2020 | 1422 | 0.030 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2018 | 197 | 0.030 |
Why?
| | Pulmonary Artery | 3 | 2011 | 1024 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 301 | 0.030 |
Why?
| | Marfan Syndrome | 1 | 2016 | 43 | 0.030 |
Why?
| | Patient Discharge | 1 | 2022 | 770 | 0.030 |
Why?
| | Bioprosthesis | 1 | 2016 | 36 | 0.030 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2018 | 437 | 0.030 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2017 | 224 | 0.030 |
Why?
| | Stress, Mechanical | 1 | 2017 | 445 | 0.030 |
Why?
| | Rats | 2 | 2018 | 4913 | 0.030 |
Why?
| | Tensins | 1 | 2014 | 2 | 0.030 |
Why?
| | Aminosalicylic Acids | 1 | 2014 | 5 | 0.030 |
Why?
| | Hydrogels | 1 | 2001 | 573 | 0.030 |
Why?
| | Thrombelastography | 1 | 2015 | 129 | 0.030 |
Why?
| | Benzenesulfonates | 1 | 2014 | 19 | 0.030 |
Why?
| | Vascular Resistance | 2 | 2011 | 340 | 0.030 |
Why?
| | Administration, Inhalation | 2 | 2006 | 637 | 0.030 |
Why?
| | Immunoblotting | 1 | 2015 | 282 | 0.030 |
Why?
| | Adolescent | 3 | 2023 | 17800 | 0.030 |
Why?
| | Coronary Angiography | 1 | 2016 | 308 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2006 | 1003 | 0.030 |
Why?
| | Insulin | 1 | 2023 | 2080 | 0.030 |
Why?
| | Cell Adhesion Molecules | 1 | 2015 | 167 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2014 | 160 | 0.030 |
Why?
| | Myocytes, Cardiac | 1 | 2018 | 449 | 0.030 |
Why?
| | Intraoperative Period | 1 | 2013 | 51 | 0.030 |
Why?
| | Chronic Disease | 1 | 2019 | 1577 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2014 | 438 | 0.030 |
Why?
| | Body Mass Index | 1 | 2020 | 1957 | 0.030 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 518 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2015 | 924 | 0.030 |
Why?
| | Down-Regulation | 1 | 2015 | 594 | 0.030 |
Why?
| | Smoking | 1 | 2019 | 1382 | 0.030 |
Why?
| | Osteopontin | 1 | 2012 | 32 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2020 | 2550 | 0.030 |
Why?
| | Hypertension | 1 | 2020 | 1052 | 0.030 |
Why?
| | Prevalence | 1 | 2018 | 2247 | 0.020 |
Why?
| | Analgesics, Opioid | 1 | 2019 | 771 | 0.020 |
Why?
| | Postoperative Hemorrhage | 1 | 2012 | 74 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2017 | 1947 | 0.020 |
Why?
| | Pravastatin | 1 | 2011 | 28 | 0.020 |
Why?
| | Diabetes Mellitus | 1 | 2019 | 898 | 0.020 |
Why?
| | Radiotherapy | 1 | 2012 | 175 | 0.020 |
Why?
| | Heptanoic Acids | 1 | 2011 | 60 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2019 | 2764 | 0.020 |
Why?
| | Emergency Treatment | 1 | 2012 | 113 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2012 | 184 | 0.020 |
Why?
| | Peptidoglycan | 1 | 2011 | 25 | 0.020 |
Why?
| | Mice, Mutant Strains | 1 | 2011 | 271 | 0.020 |
Why?
| | Culture Media | 1 | 2011 | 155 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2020 | 2322 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2018 | 1880 | 0.020 |
Why?
| | Pyrroles | 1 | 2011 | 181 | 0.020 |
Why?
| | Hospital Costs | 1 | 2010 | 104 | 0.020 |
Why?
| | Chi-Square Distribution | 1 | 2010 | 492 | 0.020 |
Why?
| | Neoplasm Metastasis | 1 | 2011 | 521 | 0.020 |
Why?
| | Regression Analysis | 1 | 2011 | 945 | 0.020 |
Why?
| | Device Removal | 1 | 2009 | 123 | 0.020 |
Why?
| | Suicide | 1 | 2014 | 507 | 0.020 |
Why?
| | Odds Ratio | 1 | 2010 | 951 | 0.020 |
Why?
| | Biopsy | 1 | 2011 | 1024 | 0.020 |
Why?
| | Equipment Design | 1 | 2009 | 503 | 0.020 |
Why?
| | Partial Pressure | 1 | 2006 | 30 | 0.020 |
Why?
| | Respiration, Artificial | 1 | 2010 | 528 | 0.020 |
Why?
| | Gases | 1 | 2006 | 38 | 0.020 |
Why?
| | Osmolar Concentration | 1 | 2006 | 169 | 0.020 |
Why?
| | Pressure | 1 | 2006 | 214 | 0.020 |
Why?
| | Logistic Models | 1 | 2010 | 1829 | 0.020 |
Why?
| | Motor Skills | 1 | 2006 | 82 | 0.020 |
Why?
| | Antibodies, Monoclonal | 1 | 2011 | 1257 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2006 | 370 | 0.010 |
Why?
| | Arteries | 1 | 2006 | 246 | 0.010 |
Why?
| | Hyperoxia | 1 | 2005 | 99 | 0.010 |
Why?
| | Algorithms | 1 | 2011 | 1469 | 0.010 |
Why?
| | Cell Differentiation | 1 | 2011 | 1696 | 0.010 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2006 | 580 | 0.010 |
Why?
| | Heart Function Tests | 1 | 2003 | 60 | 0.010 |
Why?
| | Fatigue | 1 | 2005 | 294 | 0.010 |
Why?
| | Clavicle | 1 | 2003 | 30 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2004 | 291 | 0.010 |
Why?
| | Child, Preschool | 2 | 2006 | 9114 | 0.010 |
Why?
| | Infant | 2 | 2006 | 7943 | 0.010 |
Why?
| | Stroke Volume | 1 | 2004 | 513 | 0.010 |
Why?
| | Proteins | 1 | 2006 | 906 | 0.010 |
Why?
| | Patient Satisfaction | 1 | 2003 | 571 | 0.010 |
Why?
| | Hypertonic Solutions | 1 | 1997 | 7 | 0.010 |
Why?
| | Atrial Function, Left | 1 | 1997 | 6 | 0.010 |
Why?
| | Buffers | 1 | 1997 | 53 | 0.010 |
Why?
| | Lung Compliance | 1 | 1997 | 47 | 0.010 |
Why?
| | Tidal Volume | 1 | 1997 | 75 | 0.010 |
Why?
| | Dextrans | 1 | 1997 | 73 | 0.010 |
Why?
| | Blood | 1 | 1997 | 94 | 0.010 |
Why?
| | Cryopreservation | 1 | 1997 | 92 | 0.010 |
Why?
| | Hypertension, Pulmonary | 1 | 2006 | 1736 | 0.010 |
Why?
| | Child | 1 | 2006 | 18401 | 0.000 |
Why?
|
|
Reece's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|